Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 220

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 220
---
     0 |   |
| Expected term           |     |              |    10 |   |
| Exercise price (USD)    |     |              |   0.3 |   |

| d. | On December 31, 2024, Company’s president and Chief Operating                                                                 
 Officer exercised 2,800,000 option into 2,800,000 common stock. Each option had an exercise price of $0.001 per common stock. |

Share-based
expenses recognized in the financial statements:

|                                     |     | Successor 
 2024      | For the period commencing July 24 
                           through 
                       December 31 |     | Predecessor 
 2024        | For the period commencing January 1 
                             through 
                             July 23 |     | 2023 | For the year ended 
       December 31, |
|:------------------------------------|:----|:----------|----------------------------------:|:----|:------------|------------------------------------:|:----|:-----|-------------------:|
| Research and development expenses   |     |           |                               709 |     |             |                                 710 |     |      |                205 |
| General and administrative expenses |     |           |                               580 |     |             |                                   - |     |      |                  - |
| Net loss and comprehensive loss     |     |           |                             1,289 |     |             |                                 710 |     |      |                205 |

<div align='center'>F-28</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

|                                              |     | Predecessor       |        |     |          |     |     |                                              |      |     |                           |   |
|                                              |     | Number of options |        |     | Weighted 
 average  
 exercise 
 price    |     |     | Weighted average remaining contractual terms 
 (in years)                                   |      |     | Aggregate intrinsic value |   |
| Outstanding at December 31, 2023             |     |                   |  5,657 |     |          | 100 |     |                                              | 9.88 |     |                           | - |
| Grants                                       |     |                   |  8,600 |     |          | 100 |